JNJ - Johnson & Johnson

NYSE - NYSE Delayed Price. Currency in USD
126.76
+0.57 (+0.45%)
At close: 4:00PM EDT

127.06 +0.30 (0.24%)
Pre-Market: 5:41AM EDT

Stock chart is not supported by your current browser
Previous Close126.19
Open125.91
Bid126.15 x 100
Ask126.91 x 100
Day's Range125.28 - 126.85
52 Week Range122.15 - 148.32
Volume5,859,592
Avg. Volume8,031,553
Market Cap340.051B
Beta0.59
PE Ratio (TTM)267.43
EPS (TTM)0.47
Earnings DateJul 17, 2018
Forward Dividend & Yield3.36 (2.57%)
Ex-Dividend Date2018-02-26
1y Target Est145.10
Trade prices are not sourced from all markets
  • Reuters7 hours ago

    Johnson & Johnson wins appeal to overturn $151 million hip implant verdict

    The 5th U.S. Circuit Court of Appeals said two of the plaintiffs' defective marketing claims were legally insufficient and a new trial was required overall in the case because of a judge's evidentiary rulings and "deceptions" by their lawyer. U.S. Circuit Judge Jerry Smith, writing for the three-judge panel, said U.S. District Judge Ed Kinkeade in Dallas erred in allowing the hip implant recipients' lawyers to present certain "inflammatory character evidence" about J&J. Smith said the "most problematic evidence" were bribes J&J paid to "henchmen" of Saddam Hussein in Iraq, allegations stemming from the company's agreement in 2011 to pay $70 million to resolve U.S. foreign bribery probes.

  • Reuters7 hours ago

    J&J wins appeal to overturn $151 million hip implant verdict

    Johnson & Johnson on Wednesday secured a favorable U.S. appellate court ruling, overturning a verdict that had awarded $151 million to five people who blamed injuries they suffered on the company's Pinnacle hip implant devices. The 5th U.S. Circuit Court of Appeals said two of the plaintiffs' defective marketing claims were legally insufficient and a new trial was required overall in the case because of a judge's evidentiary rulings and "deceptions" by their lawyer. U.S. Circuit Judge Jerry Smith, writing for the three-judge panel, said U.S. District Judge Ed Kinkeade in Dallas erred in allowing the hip implant recipients' lawyers to present certain "inflammatory character evidence" about J&J.

  • J&J Gets Court to Throw Out $151 Million Artificial Hip Verdict
    Bloomberg12 hours ago

    J&J Gets Court to Throw Out $151 Million Artificial Hip Verdict

    Johnson & Johnson persuaded an appeals court to throw out a $151 million award against the company over its Pinnacle artificial hips in a ruling that will affect thousands of lawsuits over the devices. A judge’s error in allowing hip recipients’ lawyers to use “highly prejudicial” evidence about bribes paid by officials of J&J units in their 2016 case mandated the jury verdict’s reversal, the New Orleans-based appeals court concluded Wednesday. Mark Lanier, the plaintiffs’ lawyer, said Wednesday he’s ready to retry the case immediately.

  • InvestorPlace18 hours ago

    Buy the Post-Earnings Lull from Johnson & Johnson

    It could have been worse for Johnson & Johnson (NYSE:JNJ) last quarter, although given the slightly bearish response from JNJ stock last week, the market also thinks it could have been better. Better still, the company’s got a plan to further beef up its research and development without taking anything away from shareholders. For the quarter ending in March, Johnson & Johnson turned $20.0 billion in revenue into an operating profit of $2.06 per share.

  • Novartis Launches FocalView to Modernize Clinical Trials
    Market Realist19 hours ago

    Novartis Launches FocalView to Modernize Clinical Trials

    Novartis (NVS), a leading pharmaceutical company, includes therapies for retinal disorders, dry eyes, glaucoma, and other eye disorders in its ophthalmology portfolio. On April 25, Novartis launched FocalView, an ophthalmic digital research app created with the help of Apple’s ResearchKit.

  • Amgen’s Earnings Grow 12% Year-Over-Year in 1Q18
    Market Realist19 hours ago

    Amgen’s Earnings Grow 12% Year-Over-Year in 1Q18

    In 1Q18, Amgen (AMGN) generated revenue of $5.6 billion, representing ~2% YoY (year-over-year) growth from its revenue of $5.5 billion in 1Q17. Quarter-over-quarter, its revenue fell ~4%. Amgen’s GAAP (generally accepted accounting principles) operating income and net income rose ~5% and ~12% YoY, respectively, to $2.7 billion and $2.3 billion from $2.6 billion and $2.1 billion.

  • How Analysts Rate Bristol-Myers Squibb in 1Q18
    Market Realist20 hours ago

    How Analysts Rate Bristol-Myers Squibb in 1Q18

    Wall Street analysts estimate Bristol-Myers Squibb’s top line to rise 6.5% to ~$5.2 billion in 1Q18. Also, the earnings per share are expected at $0.85 for 1Q18. The revenue growth is expected to be driven by the prioritized brands including Opdivo, Empliciti, Eliquis, Orencia, Sprycel, and Yervoy, partially offset by lower sales of established brands.

  • How Did Johnson & Johnson’s Consumer Segment Perform in 1Q18?
    Market Realist22 hours ago

    How Did Johnson & Johnson’s Consumer Segment Perform in 1Q18?

    Johnson & Johnson’s (JNJ) consumer business includes various beauty products, baby care products, oral care products, over-the-counter products, women’s health products, and wound care products. The company’s consumer business reported 5.3% growth in revenues to $3.4 billion during 1Q18 as compared to $3.2 billion during 1Q17. The above chart compares the revenues of the various franchises in the consumer segment business since 1Q17.

  • The Zacks Analyst Blog Highlights: Johnson & Johnson, Honeywell, Morgan Stanley, Novartis and eBay
    Zacks23 hours ago

    The Zacks Analyst Blog Highlights: Johnson & Johnson, Honeywell, Morgan Stanley, Novartis and eBay

    The Zacks Analyst Blog Highlights: Johnson & Johnson, Honeywell, Morgan Stanley, Novartis and eBay

  • What Do Analysts Predict for Bristol-Myers Squibb in 1Q18?
    Market Realist23 hours ago

    What Do Analysts Predict for Bristol-Myers Squibb in 1Q18?

    Headquartered in New York City, Bristol-Myers Squibb (BMY) is one of the leading American pharmaceutical companies. Bristol-Myers Squibb’s portfolio includes various cardiovascular products, neuroscience products, immunoscience products, oncology products, and virology products.

  • How Johnson & Johnson’s Medical Devices Segment Performed in 1Q18
    Market Realist23 hours ago

    How Johnson & Johnson’s Medical Devices Segment Performed in 1Q18

    Johnson & Johnson’s (JNJ) medical devices business includes cardiovascular care products, orthopedics products, surgery products, vision care products, and diabetes products. The medical devices business reported 7.5% growth in revenues to $6.8 billion during 1Q18 as compared to revenues of $6.3 billion during 1Q17. The growth includes 3.2% growth in revenues at constant exchange rates and a 4.3% increase due to the positive impact of foreign exchange.

  • Top Research Reports for Johnson & Johnson, Honeywell & Morgan Stanley
    Zacks2 days ago

    Top Research Reports for Johnson & Johnson, Honeywell & Morgan Stanley

    Top Research Reports for Johnson & Johnson, Honeywell & Morgan Stanley

  • Johnson & Johnson to Participate in the 2018 Deutsche Bank 43rd Annual Health Care Conference
    PR Newswire2 days ago

    Johnson & Johnson to Participate in the 2018 Deutsche Bank 43rd Annual Health Care Conference

    NEW BRUNSWICK, N.J. , April 24, 2018 /PRNewswire/ -- Johnson & Johnson (NYSE: JNJ) will participate in the 2018 Deutsche Bank 43 rd Annual Health Care Conference on Wednesday, May 9 th , at The InterContinental ...

  • Biktarvy Could Be a Major Driver for Gilead Sciences in 2018
    Market Realist2 days ago

    Biktarvy Could Be a Major Driver for Gilead Sciences in 2018

    Gilead Sciences (GILD) is planning to launch a novel HIV drug, Biktarvy, in the United States and Europe in 1H18. On February 7, Gilead secured FDA approval for Biktarvy, which is an unboosted integrase strand transfer inhibitor, bictegravir, combined with a dual nucleoside reverse transcriptase inhibitor backbone, Descovy, as an STR (single tablet regimen) for HIV-1 infected patients. Biktarvy, a differentiated HIV-1 regimen

  • Analyzing Johnson & Johnson’s Segment-Wise Performance in 1Q18
    Market Realist2 days ago

    Analyzing Johnson & Johnson’s Segment-Wise Performance in 1Q18

    Johnson & Johnson (JNJ) reported 8.4% growth in operating revenues and a 4.2% positive impact of foreign exchange to $20.0 billion in 1Q18 as compared to revenues of $17.8 billion during 1Q17. Johnson & Johnson reported growth across all three of its segments: the pharmaceutical segment, the consumer health segment, and the medical devices segment.

  • Johnson & Johnson’s Revenues Continued to Rise in 1Q18
    Market Realist3 days ago

    Johnson & Johnson’s Revenues Continued to Rise in 1Q18

    Johnson & Johnson (JNJ) reported 12.6% growth in its revenues to $20.0 billion during 1Q18 as compared to revenues of $17.8 billion during 1Q17. The company surpassed Wall Street analyst estimates for EPS (earnings per share) and revenues and reported EPS of $2.06 on revenues of $20.0 billion during 1Q18 against estimates for EPS of $2.00 on revenues of $19.4 billion during 1Q17.

  • Analysts’ Estimates for Eli Lilly & Co.’s 1Q18 Earnings
    Market Realist3 days ago

    Analysts’ Estimates for Eli Lilly & Co.’s 1Q18 Earnings

    Eli Lilly & Co. (LLY) is a leading US-based pharmaceutical company with a product portfolio covering human health products and animal health products. Eli Lilly is set to release its 1Q18 earnings on April 24.

  • Motley Fool3 days ago

    Johnson & Johnson's Top-Line Growth Isn't What It Seems

    The company’s double-digit growth comes with some caveats.

  • Geron Corporation: The Clock Is Ticking
    Motley Fool3 days ago

    Geron Corporation: The Clock Is Ticking

    Geron's stock has been a magnet for short-sellers, but the long thesis remains intact.

  • Why GlaxoSmithKline’s 1Q18 Revenues Are Expected to Fall
    Market Realist3 days ago

    Why GlaxoSmithKline’s 1Q18 Revenues Are Expected to Fall

    As discussed in the previous article, analysts expect a 2.2% decrease in GlaxoSmithKline’s (GSK) 1Q18 revenues to 7.2 billion pounds due to the impact of divestitures, the negative impact of foreign exchange, and lower sales of some products.

  • Merck’s Relebactam Met Primary Endpoints in Phase 3 Study
    Market Realist3 days ago

    Merck’s Relebactam Met Primary Endpoints in Phase 3 Study

    Merck’s (MRK) Relebactam is an investigational beta-lactamase inhibitor for the treatment of certain forms of imipenem-non-susceptible bacterial infections.

  • Reuters3 days ago

    British businesses embrace profits with a purpose

    Like many combat veterans, Steve Hammond struggled for years after returning to civilian life, battling physical injuries that made it difficult to find a job and left him contemplating suicide. Now the 61-year-old father of two is thriving as a team leader with Britain's Bravest Manufacturing Company (BBMC), one of a growing number of socially-minded companies providing jobs for people marginalised from the traditional workforce. "It gives people with a disability or mental health issues a purpose in life," Hammond, who was wounded in the Falklands War, told the Thomson Reuters Foundation.

  • 3 Things You Should Know About Today's Top Entrepreneurs
    Motley Fool4 days ago

    3 Things You Should Know About Today's Top Entrepreneurs

    A new wave of innovation will change several of America's most established industries. Here are three important takeaways for investors.

  • Motley Fool4 days ago

    Johnson & Johnson's First-Quarter 2018 Earnings Review

    We discuss the pros and cons for J&J’s latest quarterly results, plus Alkermes gets a do-over and Celldex flops.